報價延遲最少15分鐘:2025/07/21 07:21 EDT
盤前時段
|
||||
|
-- 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.46
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.85/-1.63
|
|
企業價值
1.17B
|
| 資產負債 |
|
每股賬面淨值
2.50
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
23.68M
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/21 07:21 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States. |
